Myriad Genetics Inc
Closed
SectorHealthcare
3.05 -2.24
Overview
Share price change
24h
Min
3.03
Max
3.25
Income | -9.1M -43M |
|---|---|
Sales | -9.7M 191M |
EPS | -0.33 |
Profit margin | -22.653 |
Employees | 2,700 |
EBITDA | -21M -39M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +81.07% upside |
Next Earnings | 2 Nov 2026 |
|---|
Market Cap | -230M 285M |
|---|---|
Previous open | 5.29 |
Previous close | 3.05 |
Myriad Genetics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Myriad Genetics Inc Forecast
Price Target
By TipRanks
81.07% upside
12 Months Forecast
Average 5.74 USD 81.07%
High 10 USD
Low 3 USD
Based on 6 Wall Street analysts offering 12 month price targets forMyriad Genetics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Myriad Genetics Inc
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
